No Data
No Data
Amgen (AMGN) Rose Owing To The Announcement Of Promising Data For Its Novel Medication
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
U.S. Tweaks 2025 Medicare Price Negotiation Process
Amgen (NASDAQ:AMGN) Has A Somewhat Strained Balance Sheet
Eli Lilly and Co (LLY.US) explores new uses for 'weight-loss miracle drug' Zepbound, aiming to reduce the incidence of high-risk populations such as diabetes.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report